HBeAg-positive -negative / HBeAg Seroconversion


Over Time, HBeAg-positive Chronic Hepatitis B Patients Experience Increasing - 5/02/05

Peginterferon Alfa-2a (Pegasys) Produces a Sustained Response in HBeAg-negative HBV Patients One Year after the End of Treatment  - 4/25/05

HBV DNA Plasma Levels Do Matter - 4/22/05

Factors Predicting Response to Pegylated Interferon in HBeAg Positive Chronic Hepatitis B - 4/22/05

Peginterferon Alfa-2a (Pegasys) Versus Peginterferon Alfa-2a Plus Lamivudine Versus Lamivudine In HBeAg Positive Chronic HBV - 4/18/05

Sustained HBsAg Seroconversion in Patients with Chronic HBV Treated with Peginterferon Alfa 2a (Pegasys) - 4/18/05

Greater HBV Suppression with Lamivudine (Epivir-HBV) +/- Peginterferon Alfa-2a (Pegasys) Does Not Translate into Improved Rates of Sustained HBeAg Seroconversion  - 4/18/05